Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Genitourinary 2Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Atorvastatin × Genitourinary × 1 year × Clear all
NCT03819101 2026-05-06

PEACE-4

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,210 enrolled
Genitourinary

Prostatic Neoplasms

NCT05796973 2025-06-27

MOVES

Tampere University Hospital

Phase 3 Recruiting
240 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡